NO982276L - Fremgangsmöte for behandling av retinal ganglioncelleskade under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF) - Google Patents

Fremgangsmöte for behandling av retinal ganglioncelleskade under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)

Info

Publication number
NO982276L
NO982276L NO982276A NO982276A NO982276L NO 982276 L NO982276 L NO 982276L NO 982276 A NO982276 A NO 982276A NO 982276 A NO982276 A NO 982276A NO 982276 L NO982276 L NO 982276L
Authority
NO
Norway
Prior art keywords
gdnf
neurotrophic factor
derived neurotrophic
procedure
treatment
Prior art date
Application number
NO982276A
Other languages
English (en)
Norwegian (no)
Other versions
NO982276D0 (no
Inventor
Qiao Yan
Jean-Claude Marcel Louis
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO982276D0 publication Critical patent/NO982276D0/no
Publication of NO982276L publication Critical patent/NO982276L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO982276A 1995-11-29 1998-05-19 Fremgangsmöte for behandling av retinal ganglioncelleskade under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF) NO982276L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/564,458 US5641749A (en) 1995-11-29 1995-11-29 Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
PCT/US1996/018851 WO1997019695A1 (en) 1995-11-29 1996-11-22 Method for treating retinal ganglion cell injury using glial cell line-derived neurotrophic factor (gdnf) protein product

Publications (2)

Publication Number Publication Date
NO982276D0 NO982276D0 (no) 1998-05-19
NO982276L true NO982276L (no) 1998-07-29

Family

ID=24254557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982276A NO982276L (no) 1995-11-29 1998-05-19 Fremgangsmöte for behandling av retinal ganglioncelleskade under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)

Country Status (20)

Country Link
US (1) US5641749A (da)
EP (1) EP0866719B1 (da)
JP (1) JP4066201B2 (da)
KR (1) KR19990071541A (da)
CN (1) CN1203531A (da)
AT (1) ATE194081T1 (da)
BR (1) BR9611748A (da)
CA (1) CA2236158C (da)
CZ (1) CZ149998A3 (da)
DE (1) DE69609084T2 (da)
DK (1) DK0866719T3 (da)
ES (1) ES2148826T3 (da)
GR (1) GR3034194T3 (da)
HU (1) HUP0001078A2 (da)
IL (1) IL124600A0 (da)
MX (1) MX9803968A (da)
NO (1) NO982276L (da)
PT (1) PT866719E (da)
SK (1) SK65898A3 (da)
WO (1) WO1997019695A1 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064870A1 (en) * 1993-03-03 2002-05-30 Pascale Briand Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2710846B1 (fr) 1993-10-04 1995-12-22 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
US8431119B2 (en) * 1993-10-04 2013-04-30 Aventis Pharma S.A. Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US7276251B2 (en) * 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
WO1998010785A1 (fr) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Compositions ophtalmiques de facteurs neurotrophiques, remedes pour troubles fonctionnels du nerf optique et procede de traitement de tels troubles
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
US20030121064A1 (en) * 1997-06-11 2003-06-26 Ann Logan CNS neuroregenerative compositions and methods of use
AU9198898A (en) * 1997-09-17 1999-04-05 Alcon Laboratories, Inc. Methods for treating ocular diseases
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6906077B1 (en) * 1998-12-03 2005-06-14 Alcon Manufacturing, Ltd. Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
IT1305294B1 (it) 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
AU3755900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US7653769B2 (en) * 2006-12-14 2010-01-26 International Business Machines Corporation Management of devices connected to infiniband ports
JP2002223748A (ja) * 2001-01-31 2002-08-13 Norio Sakuragawa 網膜神経節細胞培養用培地、眼科用組成物及び網膜神経節細胞保護剤
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
AU2002346611A1 (en) * 2001-12-03 2003-06-17 The Regents Of The University Of California Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
US20030158112A1 (en) * 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
AU2003297607A1 (en) * 2002-12-02 2004-06-23 Genvec, Inc Materials and methods for treating ocular-related disorders
NZ543365A (en) 2003-04-18 2009-02-28 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
JP4168275B2 (ja) * 2003-11-17 2008-10-22 株式会社島津製作所 重量測定装置
US20050260180A1 (en) * 2004-03-12 2005-11-24 Genvec, Inc. Materials and methods for treating vascular leakage in the eye
US8722862B2 (en) * 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
EA013565B1 (ru) * 2004-08-19 2010-06-30 Байоджен Айдек Ма Инк. Варианты полипептидов нейбластина, способы их получения и их применение
US20060083734A1 (en) * 2004-10-18 2006-04-20 Henrich Cheng Composition and method for repairing nerve damage and enhancing functional recovery of nerve
US20060188481A1 (en) * 2005-02-22 2006-08-24 Saitama Medical School Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
US8877229B2 (en) * 2005-12-02 2014-11-04 Eyetech Inc. Controlled release microparticles
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (en) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Compostions and methods for administering gdnf ligand family proteins
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
EP2968462B1 (en) 2013-03-15 2020-12-23 The Jackson Laboratory Methods for promoting wound healing and hair growth
SG10201810150UA (en) 2014-03-17 2018-12-28 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
US10874798B2 (en) * 2014-10-15 2020-12-29 P&X Medical Nv Therapeutic applications of artificial cerebrospinal fluid and tools provided therefor
CN107405507B (zh) 2015-03-02 2022-05-03 阿德夫拉姆生物技术股份有限公司 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
DK3081263T3 (da) 2015-04-17 2020-03-16 P&X Medical Nv Sammensætninger og redskaber til behandling af glaukom
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
EP3538560A4 (en) 2016-11-10 2020-06-17 Keros Therapeutics, Inc. GDNF FUSION POLYPEPTIDES AND METHODS OF USE
US11541005B2 (en) * 2017-02-08 2023-01-03 New Hope Research Foundation, Inc. Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord
US11723865B2 (en) * 2017-02-08 2023-08-15 New Hope Research Foundation, Inc. Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3995635A (en) * 1971-09-09 1976-12-07 Alza Corporation Ocular insert
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4217898A (en) * 1978-10-23 1980-08-19 Alza Corporation System with microporous reservoir having surface for diffusional delivery of agent
US4474452A (en) * 1981-05-13 1984-10-02 Pitney Bowes Inc. Safety device for cam yoke used in electrophotocopier reciprocating carriage
JPS5823043A (ja) * 1981-08-03 1983-02-10 Fuji Xerox Co Ltd 複写機の濃度自動制御方法
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US4882150A (en) * 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
EP1241258A3 (en) * 1989-10-16 2003-12-10 Amgen Inc. Stem cell factor
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
GEP20002243B (en) * 1991-09-20 2000-09-25 Amgen Inc Glial Derived Neurotrophic Factor
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
AU677951B2 (en) * 1992-02-14 1997-05-15 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
AU1443095A (en) * 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent

Also Published As

Publication number Publication date
AU696772B2 (en) 1998-09-17
WO1997019695A1 (en) 1997-06-05
DK0866719T3 (da) 2000-08-28
NO982276D0 (no) 1998-05-19
JP4066201B2 (ja) 2008-03-26
SK65898A3 (en) 1999-01-11
US5641749A (en) 1997-06-24
CA2236158A1 (en) 1997-06-05
DE69609084D1 (de) 2000-08-03
CN1203531A (zh) 1998-12-30
KR19990071541A (ko) 1999-09-27
BR9611748A (pt) 1999-06-01
ATE194081T1 (de) 2000-07-15
IL124600A0 (en) 1998-12-06
HUP0001078A2 (hu) 2000-08-28
CZ149998A3 (cs) 1998-08-12
MX9803968A (es) 1998-09-30
AU1163197A (en) 1997-06-19
EP0866719B1 (en) 2000-06-28
PT866719E (pt) 2000-11-30
CA2236158C (en) 2002-07-16
ES2148826T3 (es) 2000-10-16
EP0866719A1 (en) 1998-09-30
GR3034194T3 (en) 2000-11-30
JP2000501393A (ja) 2000-02-08
DE69609084T2 (de) 2000-11-16

Similar Documents

Publication Publication Date Title
NO982276L (no) Fremgangsmöte for behandling av retinal ganglioncelleskade under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
NO974767L (no) Anvendelse av glianeurotrof faktor (GDNF) til behandling av hörselsforstyrrelser
DK0852585T3 (da) Fremgangsmåde til behandling af Alzheimer's sygdom ved anvendelse af gliacelleafledt neurotrofisk faktor (GDNF)-proteinprodukt
DK0863766T3 (da) Fremgangsmåde til behandling af skade eller degenerering af fotoreceptorer under anvendelse af et glialcellelinjeafledt neu
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
EA199900464A1 (ru) Способы и композиции для стимуляции роста невритов
AU8658298A (en) Method for preventing and treating hearing loss using a neurturin protein product
ZA964852B (en) Methods and compositions for stimulating neurite growth
DK0920448T3 (da) Trunkeret gliacellelinie-afledt neurotrof faktor
WO2003031643A3 (en) Methods for regulating co-stimulatory molecule expression with reactive oxygen
GB9811279D0 (en) Keratinocyte growth factor-2 products
AR022685A1 (es) Uso de estimulantes de factores neurotroficos para el tratamiento de enfermedades neurodegenerativas oftalmicas.
NO981687L (no) Lubeluzol N-oksid
WO2002066620A3 (de) Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
MX9709829A (es) Metodos y composiciones para estimular el crecimiento de neurita.